

Navigating Biosimilars: Translating Evidence Into Clinical Practice

Clinical Pearls

Patients with various inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease, have achieved remarkable benefits when treated with biologics. However, the limited patient access to these medications, due to high costs, led to the creation of a regulatory pathway for the development of biosimilars. Several biosimilars have been approved for use in the United States. This CME-certified activity, *Navigating Biosimilars: Translating Evidence Into Clinical Practice* is intended to help health care providers navigate their way through the evolving world of biosimilars so that they can make informed choices about the use of these biologics in clinical practice.

Patients may not take a biologic as prescribed

- The rate of prescription abandonment increases as the out-of-pocket expenditure increases
- Out-of-pocket expenditures for biologics continue to increase

The production of a biologic is complicated and leads to batch-to-batch variation

- Biologics are large, complex molecules of variable structure, whereas small-molecule drugs have a simple, well-defined, relatively stable structure
- The manufacturing of a biologic results in a mixture of molecular structures with slight differences
- Manufacturers of biologics are required to demonstrate comparability of a new batch with previous batches

A biosimilar is not a generic version of its reference product

- Similarly, a biosimilar is not a biobetter of its reference product

A biosimilar must be shown to be highly similar to its reference product in terms of safety, purity, and potency

- The regulatory pathway for biosimilar development is a stepwise, scientifically rigorous process
- A totality-of-evidence approach is utilized to demonstrate biosimilarity
- No differences in safety or efficacy are expected between a biosimilar and its reference product

Biosimilars are reverse engineered

- Development begins with the utilization of information about the reference product that is in the public domain
- Extensive analytical and preclinical studies are utilized, more so than clinical studies
- A phase 3 clinical study is utilized to resolve any remaining uncertainty about the biosimilar being highly similar to its reference product

A biosimilar may be approved for multiple indications by extrapolation

- Biosimilar must be shown to be physicochemically, immunochemically, pharmacokinetically, and pharmacodynamically similar to the reference product
- Biosimilar must be shown to be efficacious and safe in one of the diseases for which the reference product is approved

A biosimilar may be approved as interchangeable with its reference product

- Interchangeability requires that the biosimilar meet a higher set of standards than those required for demonstrating biosimilarity
- Product approved as interchangeable may be substituted for the reference product by a pharmacist according to state law
- As of December 2017, no biosimilars have been approved as interchangeable

Following the availability of biosimilars, early evidence indicates greater use of biologics

- Lower cost of a biosimilar often leads to lower cost of its reference product
- Overall expenditures for biologics for which a biosimilar has been approved appear to be declining

Pharmacovigilance plays an important role in biosimilar development

- Pharmacovigilance plays a key role in determining the safety and efficacy of a biosimilar in the real world
- Registries, real-time data, accurate tracking, and health care provider communication and reporting potentially play important roles in pharmacovigilance

There are several suggestions providers may wish to keep in mind regarding biosimilars

- Be aware of which biosimilar product is being prescribed, dispensed, and used
- Prescribe using the proper name or trade name with suffix
- Contribute to local pharmacovigilance efforts
- Monitor long-term safety

Patients are in need of education about biosimilars

- A survey of persons in the United States and Europe showed low awareness about biosimilars
- Persons who are aware of biosimilars are generally more comfortable regarding the safety and efficacy of biosimilars than persons who are not aware of biosimilars
- Affordability and access to treatment are major concerns of patients

This program has reviewed the stepwise, scientifically rigorous, totality-of-evidence process required for the development of biosimilars to demonstrate that there are no clinically meaningful differences in safety, purity, or potency between the biosimilar and its reference product. Other issues discussed include extrapolation, naming, and interchangeability, as well as suggestions for integrating biosimilars into clinical practice, including educating patients. With this greater understanding, we anticipate you are better able to navigate biosimilars and translate the evidence into your clinical practice

References

- Aspirin [package insert]. Whippany, NJ, Bayer Consumer Healthcare; 2014.
- Atzinger CB, Guo JJ. Biologic disease-modifying antirheumatic drugs in a national privately insured population: Utilization, expenditures, and price trends. *Am Health Drug Benefits*. 2017;10(1):27-36.
- Casadevall N, Edwards IR, Felix T, et al. Pharmacovigilance and biosimilars: considerations, needs and challenges. *Expert Opin Biol Ther*. 2013;13(7):1039-1047.
- Code of Federal Regulations Title 21, Volume 7. Subchapter F-Biologics. Published April 1, 2017. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=600.3>. Accessed December 12, 2017.
- Commonwealth of Massachusetts. Chapter 143. An Act Relative to the Substitution of Biosimilars. Published June 19, 2014. <http://www.foleyhoag.com/-/media/files/foley%20hoag/publications/alert%20and%20update%20misc/2014/foley-hoag-life-sciences-alert-chapter%20143-of-acts-of-2014.ashx?la=en>. Accessed December 12, 2017.
- Commonwealth of Virginia. Chapter 412. Published March 16, 2013. <https://leg1.state.va.us/cgi-bin/legp504.exe?131+ful+CHAP0412>. Accessed December 12, 2017.
- Congress of the United States. Patient Protection and Affordable Care Act. Published March 23, 2010. <https://www.gpo.gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf>. Accessed December 12, 2017.
- Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. *Ann Rheum Dis*. 2016;75(6):974-982.
- Dörner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. *Nat Rev Rheumatol*. 2015;11(12):713-724.

- European Medicines Agency. Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Published September 1, 2015.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001378.jsp&mid=WC0b01ac058002958c. Accessed December 12, 2017.
- Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures in U.S. nonfederal hospitals and clinics-2013. *Am J Health Syst Pharm*. 2013;70(6):525-539.
- Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures-2012 *Am J Health Syst Pharm*. 2012;69(5):405-421.
- Hopson S, Saverno K, Liu LZ, et al. Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis. *J Manag Care Spec Pharm*. 2016;22(2):122-130.
- International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. Q5E. Published November 18, 2004.
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. Accessed December 12, 2017.
- Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. *Patient Prefer Adherence*. 2016; 10:937-948.
- Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. *N Engl J Med*. 2011;365(5):385-388.
- Li E, Ramanan S, Green L. Pharmacist substitution of biological products: Issues and considerations. *J Manag Care Spec Pharm*. 2015;21(7):532-539.
- Li F, Vijayasankaran N, Shen A, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. *mAbs*. 2010;2(5):466-477.
- Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. *mAbs*. 2010;2(5):480-499.
- Mulcahy AW, Predmore Z, Mattke S. The cost savings potential of biosimilar drugs in the United States. RAND Corporation. Published 2014.
https://www.rand.org/content/dam/rand/pubs/perspectives/PE100/PE127/RAND_PE127.pdf. Accessed December 12, 2017.
- National Conference of State Legislatures. State laws and legislation related to biologic medications and substitution of biosimilars. Published September 1, 2017.
<http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx>. Accessed December 12, 2017.
- Online Mendelian Inheritance in Man. Johns Hopkins University. Published January 11, 2017.
www.omim.org/entry/139250?search=human%20growth%20hormone&highlight=hormone%20growth%20human. Accessed December 12, 2017.

- Peake STC, Bernardo D, Mann ER, Al-Hassi HO, Knight SC, Hart AL. Mechanisms of action of anti-tumor necrosis factor alpha agents in Crohn's disease. *Inflamm Bowel Dis*. 2013; 19:1546-1555.
- Reichert JM. Next generation and biosimilar monoclonal antibodies: Essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany. *mAbs*. 2011;3:223-240.
- Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. *Nat Biotechnol*. 2011;29(4):310-312.
- Schneider CK, Vleminckx C, Gravanis I, et al. Setting the stage for biosimilar monoclonal antibodies. *Nat Biotechnol*. 2012;30(12):1179-1185.
- Schumock GT, Li EC, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2016. *Am J Health Syst Pharm*. 2016;73(14):1058-1075.
- Schumock GT, Li EC, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2015. *Am J Health Syst Pharm*. 2015;72(9):717-736.
- Schumock GT, Li EC, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2014. *Am J Health Syst Pharm*. 2014;71(6):482-499.
- Sigma-Aldrich. Insulin product information. Published February 2014. www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Product_Information_Sheet/2/i6634pis.pdf. Accessed December 12, 2017.
- State of Delaware. Title 24. Professions and Occupations. Chapter 25. Pharmacy. <http://delcode.delaware.gov/title24/c025/sc06/index.shtml>. Accessed December 12, 2017.
- State of Florida. CS/CS/HB 365. Published 2013. <http://www.flsenate.gov/Session/Bill/2013/0365/BillText/er/pdf>. Accessed December 12, 2017.
- US Food and Drug Administration. Therapeutic Biologics Applications (BLA). Published June 2, 2017. <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/default.htm>. Accessed December 12, 2017.
- US Food and Drug Administration. How Drugs are Developed and Approved. Published August 18, 2015. <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/default.htm>. Accessed December 12, 2017.
- US Food and Drug Administration. Guidance for Industry. Applications Covered by Section 505(b)(2). Published October 1999. <http://www.fda.gov/downloads/Drugs/.../Guidances/ucm079345.pdf>. Accessed December 12, 2017.

- US Food and Drug Administration. Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products. Published April 1996. <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122879.htm>. Accessed December 12, 2017.
- US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf>. Accessed December 12, 2017.
- US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product. Published April 2015. <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf>. Accessed December 12, 2017.
- US Food and Drug Administration. Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. Published December 5, 2017. <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm>. Accessed December 12, 2017.
- US Food and Drug Administration. Nonproprietary Naming of Biological Products. Guidance for Industry. Published January 2017. <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm459987.pdf>. Accessed December 12, 2017.
- US Food and Drug Administration. Considerations in Demonstrating Interchangeability with a Reference Product. Guidance for Industry. <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf>. Accessed December 12, 2017.
- Voynov V, Chennamsetty N, Kayser V, Helk B, Trout BL. Predictive tools for stabilization of therapeutic proteins. *mAbs*. 2009;1(6):580-582.
- Webster RM. The immune checkpoint inhibitors: where are we now? *Nat Rev Drug Discov*. 2014;13(12):883-884.
- Woodcock J, Griffin J, Behrman R, et al. The FDA's assessment of follow-on protein products: a historical perspective. *Nat Rev Drug Discov*. 2007;6(6):437-442.
- Zuñiga L, Calvo B. Biosimilars: pharmacovigilance and risk management. *Pharmacoepidemiol Drug Saf*. 2010;19(7):661-669

Additional Sources of Information

- American Gastroenterological Association
 - http://www.gastro.org/news_items/get-your-questions-answered-on-biosimilar-therapies
- Biosimilars Forum
 - <http://www.biosimilarsforum.org/about-biosimilars-forum>

- European Medicines Agency
 - http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp&mid=WCOb01ac0580bb8fda
- Generics and Biosimilars Initiative
 - <http://gabionline.net/>
 - <http://gabi-journal.net/>
- National Conference of State Legislatures
 - <http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx>
- National Psoriasis Foundation
 - <https://www.psoriasis.org/about-psoriasis/treatments/biosimilars>
- Pharmaceutical Research and Manufacturers of America
 - <http://www.phrma.org/advocacy/research-development/biologics-biosimilars>
- The Biosimilars Council
 - <http://biosimilarscouncil.org/>
- US Food and Drug Administration
 - <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm>
 - <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm290967.htm>